国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2011年
9期
795-797
,共3页
张雪梅%赵习德%裴强%臧莉
張雪梅%趙習德%裴彊%臧莉
장설매%조습덕%배강%장리
桂枝茯苓胶囊胶囊%动脉粥样硬化%oxLDL%MDA%SOD
桂枝茯苓膠囊膠囊%動脈粥樣硬化%oxLDL%MDA%SOD
계지복령효낭효낭%동맥죽양경화%oxLDL%MDA%SOD
Guizhi-FulingCapsule%Atherosclerosis%oxLDL%MDA%SOD
目的 探讨桂枝茯苓胶囊对动脉粥样硬化(atherosclerosis，AS)模型大鼠抗氧化作用的影响。方法 选用健康雄性SD大鼠50只，按随机数字表法分为空白对照组12只、造模组38只。空白组给予普通饲料喂养，造模组用高脂饮食十维生素D3腹腔注射法复制大鼠AS模型,12周末每组各抽取2只确认造模成功。造模组按随机数字表法分为3组：AS模型组、阳性对照组、中药组，每组12只。阳性对照组以辛伐他汀(0.86 mg/kg·d-1)加卡托普利(4.3 mg/kg·d-1)灌胃；中药组给予桂枝茯苓胶囊(0.24 g/kg·d-1)灌胃;AS模型组以等量生理盐水(0.24 g/kg·d-1)灌胃。药物干预4周后，测定血清氧化型低密度脂蛋白(ox-LDL)、丙二醛(MDA)和超氧化物歧化酶(SOD)水平。结果与空白对照组比较，AS模型组血清中oxLDL含量[(83.46±19.42) pg/dl]、MDA含量[(7.38±2.46) nmol/ml]显著升高(P均＜0.01); SOD含量[(135.70±23.49) nu/ml]显著降低(P＜0.01)。与AS模型组比较，阳性对照组血清中oxLDL含量[ (45.87士11.91)pg/dl]、MDA含量[(5.27±1.95) nmol/ml]，中药组oxLDL含量[(26.73土9.06) pg/dl]、MDA含量[(4.05±1.83) nmol/ml]均降低(P均＜0.01)；SOD含量[阳性对照组、中药组分别为(185.87±37.36) nu/ml、(158.65±31.48) nu/ml]均显著升高(P分别为＜0.01、＜0.05）。与阳性对照组比较，中药组血清中oxLDL、MDA含量均降低(P分别为＜0.01、＜0.05）；SOD含量均升高(P＜0.05）。结论 桂枝茯苓胶囊可通过抗氧化作用抑制动脉粥样硬化进程。
目的 探討桂枝茯苓膠囊對動脈粥樣硬化(atherosclerosis，AS)模型大鼠抗氧化作用的影響。方法 選用健康雄性SD大鼠50隻，按隨機數字錶法分為空白對照組12隻、造模組38隻。空白組給予普通飼料餵養，造模組用高脂飲食十維生素D3腹腔註射法複製大鼠AS模型,12週末每組各抽取2隻確認造模成功。造模組按隨機數字錶法分為3組：AS模型組、暘性對照組、中藥組，每組12隻。暘性對照組以辛伐他汀(0.86 mg/kg·d-1)加卡託普利(4.3 mg/kg·d-1)灌胃；中藥組給予桂枝茯苓膠囊(0.24 g/kg·d-1)灌胃;AS模型組以等量生理鹽水(0.24 g/kg·d-1)灌胃。藥物榦預4週後，測定血清氧化型低密度脂蛋白(ox-LDL)、丙二醛(MDA)和超氧化物歧化酶(SOD)水平。結果與空白對照組比較，AS模型組血清中oxLDL含量[(83.46±19.42) pg/dl]、MDA含量[(7.38±2.46) nmol/ml]顯著升高(P均＜0.01); SOD含量[(135.70±23.49) nu/ml]顯著降低(P＜0.01)。與AS模型組比較，暘性對照組血清中oxLDL含量[ (45.87士11.91)pg/dl]、MDA含量[(5.27±1.95) nmol/ml]，中藥組oxLDL含量[(26.73土9.06) pg/dl]、MDA含量[(4.05±1.83) nmol/ml]均降低(P均＜0.01)；SOD含量[暘性對照組、中藥組分彆為(185.87±37.36) nu/ml、(158.65±31.48) nu/ml]均顯著升高(P分彆為＜0.01、＜0.05）。與暘性對照組比較，中藥組血清中oxLDL、MDA含量均降低(P分彆為＜0.01、＜0.05）；SOD含量均升高(P＜0.05）。結論 桂枝茯苓膠囊可通過抗氧化作用抑製動脈粥樣硬化進程。
목적 탐토계지복령효낭대동맥죽양경화(atherosclerosis，AS)모형대서항양화작용적영향。방법 선용건강웅성SD대서50지，안수궤수자표법분위공백대조조12지、조모조38지。공백조급여보통사료위양，조모조용고지음식십유생소D3복강주사법복제대서AS모형,12주말매조각추취2지학인조모성공。조모조안수궤수자표법분위3조：AS모형조、양성대조조、중약조，매조12지。양성대조조이신벌타정(0.86 mg/kg·d-1)가잡탁보리(4.3 mg/kg·d-1)관위；중약조급여계지복령효낭(0.24 g/kg·d-1)관위;AS모형조이등량생리염수(0.24 g/kg·d-1)관위。약물간예4주후，측정혈청양화형저밀도지단백(ox-LDL)、병이철(MDA)화초양화물기화매(SOD)수평。결과여공백대조조비교，AS모형조혈청중oxLDL함량[(83.46±19.42) pg/dl]、MDA함량[(7.38±2.46) nmol/ml]현저승고(P균＜0.01); SOD함량[(135.70±23.49) nu/ml]현저강저(P＜0.01)。여AS모형조비교，양성대조조혈청중oxLDL함량[ (45.87사11.91)pg/dl]、MDA함량[(5.27±1.95) nmol/ml]，중약조oxLDL함량[(26.73토9.06) pg/dl]、MDA함량[(4.05±1.83) nmol/ml]균강저(P균＜0.01)；SOD함량[양성대조조、중약조분별위(185.87±37.36) nu/ml、(158.65±31.48) nu/ml]균현저승고(P분별위＜0.01、＜0.05）。여양성대조조비교，중약조혈청중oxLDL、MDA함량균강저(P분별위＜0.01、＜0.05）；SOD함량균승고(P＜0.05）。결론 계지복령효낭가통과항양화작용억제동맥죽양경화진정。
Objective To study antioxidation functions effect of Guizhi-Fuling Capsule in rats with atherosclerosis(AS). Methods 50 healthy SD male rats were randomly divided into 2 groups: normal group(n=12), and AS model group (n=36). The model of experimental AS rats was established by high cholesterol diet and intraperitoneal injecting Vit D3. The normal control group was fed by ordinary diet. AS model group was randomly divided into 3 groups: AS group (n= 12), control group (n= 12), therapy group (n=12). Therapy group was given Guizhi-Fuling Capsule (0.24 g/kg · d-1) , control group was given simvastafin (0.86 mg/kg · d-1 ) and captopril (4.3 mg/kg · d-1) by intragastric administration for four weeks. Oxidized-low density lipoprotein (oxLDL),malondialdehyde (MDA), superoxide dismutase(SOD) in serum were detected at the end of therapy. Results Compared with the normal group The oxLDL [ (83.46 ± 19.42)pg/dl], MDA [ (7.38 ±2.46)nmol/ml] in serum were increased significantly(both P＜0.01 ), while SOD[ (135.70±23.49)nu/ml] was decreased significantly (P＜0.01 )in AS model group. Compared with the model group, the oxLDL[(45.87± 1l.91)pg/di], MDA[ (5.27 ±1.95)nmol/ml] in serum in control group ,the oxLDL[(26.73±9.06)pg/dl], MDA[(4.05±1.83)nmol/ml] in serum in therapy group were lower significandy (all P＜0.01 ), and the lowering effect in therapy group was better than that in control group. SOD in serum was higher significantly in the two treatment groups [in control group (185.87±37.36)nu/ml (P＜0.01)、 in therapy group (158.65±31.4S) nu/ml (P＜0.05) ], and the increasing effect in therapy group was better than that in control group. Conclusion Guizhi-Fuling Capsule has the effects of resisting atherosclerosis to rats with AS. Its mechanisms maybe relate to its antioxidation functions.
